Management of Women with a Hereditary Predisposition for Breast Cancer

References

• Thompson ER , RowleySM, LiNet al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J. Clin. Oncol.34(13), 1455–1459 (2016).
   PubMed Web of Science ®Google Scholar
• Hartmann LC , LindorNM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N. Engl. J. Med.374(5), 454–468 (2016).
   PubMed Web of Science ®Google Scholar
• Sheikh A , HussainSA, GhoriQet al. The spectrum of genetic mutations in breast cancer. Asian Pac. J. Cancer Prev.16(6), 2177–2185 (2015).
   PubMedGoogle Scholar
• Evans DG , BarwellJ, EcclesDMet al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res.16(5), 442 (2014).
   PubMed Web of Science ®Google Scholar
• Turnbull C , RahmanN. Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet.9, 321–345 (2008).
   PubMed Web of Science ®Google Scholar
• Singletary SE . Rating the risk factors for breast cancer. Ann. Surg.237(4), 474–482 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson WF , JatoiI, TseJ, RosenbergPS. Male breast cancer: a population-based comparison with female breast cancer. J. Clin. Oncol.28(2), 232–239 (2010).
   PubMed Web of Science ®Google Scholar
• Mcpherson K , SteelCM, DixonJM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ321(7261), 624–628 (2000).
   PubMed Web of Science ®Google Scholar
• Oseni T , JatoiI. An overview of the role of prophylactic surgery in the management of individuals with a hereditary cancer predisposition. Surg. Clin. North Am.88(4), 739–758, vi (2008).
   PubMed Web of Science ®Google Scholar
• Jatoi I , BensonJR, LiauSSet al. The role of surgery in cancer prevention. Curr. Probl. Surg.47(10), 750–830 (2010).
   PubMed Web of Science ®Google Scholar
• Benson JR , JatoiI, KeischM, EstevaFJ, MakrisA, JordanVC. Early breast cancer. Lancet373(9673), 1463–1479 (2009).
   PubMed Web of Science ®Google Scholar
• Harvie M , HowellA, EvansDG. Can diet and lifestyle prevent breast cancer: what is the evidence?Am. Soc. Clin. Oncol. Educ. Book2015, e66–73 (2015).
   Google Scholar
• Gabai-Kapara E , LahadA, KaufmanBet al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc. Natl Acad. Sci. USA111(39), 14205–14210 (2014).
   PubMed Web of Science ®Google Scholar
• Narod SA , AmosC. Estimating the power of linkage analysis in hereditary breast cancer. Am. J. Hum. Genet.46(2), 266–272 (1990).
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr . Hereditary cancer, oncogenes, and antioncogenes. Cancer Res.45(4), 1437–1443 (1985).
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr . Genetics of human cancer. Annu. Rev. Genet.20, 231–251 (1986).
   PubMed Web of Science ®Google Scholar
• King MC , Levy-LahadE, LahadA. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA312(11), 1091–1092 (2014).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR , MitraN, WanFet al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA313(13), 1347–1361 (2015).
   PubMed Web of Science ®Google Scholar
• Hutchinson L . Screening: BRCA testing in women younger than 50 with triple-negative breast cancer is cost effective. Nat. Rev. Clin. Oncol.7(11), 611 (2010).
   PubMedGoogle Scholar
• Jatoi I . Options in breast cancer local therapy: who gets what?World J. Surg.36(7), 1498–1502 (2012).
   PubMed Web of Science ®Google Scholar
• Antoniou AC , CasadeiS, HeikkinenTet al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med.371(6), 497–506 (2014).
   PubMed Web of Science ®Google Scholar
• Mavaddat N , AntoniouAC, EastonDF, Garcia-ClosasM. Genetic susceptibility to breast cancer. Mol. Oncol.4(3), 174–191 (2010).
   PubMed Web of Science ®Google Scholar
• Lane DP , HuppTR. Drug discovery and p53. Drug Discov. Today8(8), 347–355 (2003).
   PubMed Web of Science ®Google Scholar
• Bougeard G , Renaux-PetelM, FlamanJMet al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J. Clin. Oncol.33(21), 2345–2352 (2015).
   PubMed Web of Science ®Google Scholar
• Nelen MR , PadbergGW, PeetersEAet al. Localization of the gene for Cowden disease to chromosome 10.22–23. Nat. Genet.13(1), 114–116 (1996).
   PubMed Web of Science ®Google Scholar
• Thompson D , EastonD. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia9(3), 221–236 (2004).
   PubMed Web of Science ®Google Scholar
• Antoniou AC , EastonDF. Models of genetic susceptibility to breast cancer. Oncogene25(43), 5898–5905 (2006).
   PubMed Web of Science ®Google Scholar
• Udler MS , MeyerKB, PooleyKAet al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum. Mol. Genet.18(9), 1692–1703 (2009).
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H , Van Den OuwelandA, KlijnJet al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet.31(1), 55–59 (2002).
   PubMed Web of Science ®Google Scholar
• Amir E , FreedmanOC, SerugaB, EvansDG. Assessing women at high risk of breast cancer: a review of risk assessment models. J. Natl Cancer Inst.102(10), 680–691 (2010).
   PubMed Web of Science ®Google Scholar
• Geller G , BernhardtBA, DoksumT, HelzlsouerKJ, WilcoxP, HoltzmanNA. Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women?J. Clin. Oncol.16(8), 2868–2876 (1998).
   PubMed Web of Science ®Google Scholar
• Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer . NICE Clinical Guidelines, No. 164, National Collaborating Centre for Cancer, Cardiff, UK (2013).
   Google Scholar
• Black WC , NeaseRFJr, TostesonAN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J. Natl Cancer Inst.87(10), 720–731 (1995).
   PubMed Web of Science ®Google Scholar
• Jatoi I , AndersonWF. Cancer screening. Curr. Probl. Surg.42(9), 620–682 (2005).
   PubMedGoogle Scholar
• Thomas DB , GaoDL, RayRMet al. Randomized trial of breast self-examination in Shanghai: final results. J. Natl Cancer Inst.94(19), 1445–1457 (2002).
   PubMed Web of Science ®Google Scholar
• Semiglazov VF , ManikhasAG, MoiseenkoVMet al. [Results of a prospective randomized investigation [Russia (St. Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer]. Vopr. Onkol.49(4), 434–441 (2003).
   PubMedGoogle Scholar
• Mittra I , MishraGA, SinghSet al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int. J. Cancer126(4), 976–984 (2010).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R , RamadasK, TharaSet al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J. Natl Cancer Inst.103(19), 1476–1480 (2011).
   PubMedGoogle Scholar
• Moss SM , WaleC, SmithR, EvansA, CuckleH, DuffySW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol.16(9), 1123–1132 (2015).
   PubMed Web of Science ®Google Scholar
• Miller AB , WallC, BainesCJ, SunP, ToT, NarodSA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ348, g366 (2014).
   PubMed Web of Science ®Google Scholar
• Jatoi I . The impact of advances in treatment on the efficacy of mammography screening. Prev. Med.53(3), 103–104 (2011).
   PubMed Web of Science ®Google Scholar
• Shapiro S . Periodic screening for breast cancer: the HIP randomized controlled trial. Health Insurance Plan. J. Natl Cancer Inst. Monogr. (22), 27–30 (1997).
   PubMedGoogle Scholar
• Pijpe A , AndrieuN, EastonDFet al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ345, e5660 (2012).
   PubMedGoogle Scholar
• Jatoi I . MRI in breast cancer management: potential for benefit and harm. Int. J. Fertil. Womens Med.50(6), 281–284 (2005).
   PubMedGoogle Scholar
• Kuhl C , WeigelS, SchradingSet al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J. Clin. Oncol.28(9), 1450–1457 (2010).
   PubMed Web of Science ®Google Scholar
• Fisher B , CostantinoJP, WickerhamDLet al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Powles TJ , AshleyS, TidyA, SmithIE, DowsettM. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl Cancer Inst.99(4), 283–290 (2007).
   PubMedGoogle Scholar
• Veronesi U , MaisonneuveP, RotmenszNet al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J. Natl Cancer Inst.99(9), 727–737 (2007).
   PubMedGoogle Scholar
• Cuzick J , ForbesJF, SestakIet al. Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst.99(4), 272–282 (2007).
   PubMed Web of Science ®Google Scholar
• Visvanathan K , ChlebowskiRT, HurleyPet al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol.27(19), 3235–3258 (2009).
   PubMed Web of Science ®Google Scholar
• King MC , WieandS, HaleKet al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA286(18), 2251–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Cuzick J , SestakI, CawthornSet al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol.16(1), 67–75 (2015).
   PubMed Web of Science ®Google Scholar
• Vogel VG , CostantinoJP, WickerhamDLet al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev. Res. (Phila.)3(6), 696–706 (2010).
   PubMed Web of Science ®Google Scholar
• Dowsett M , CuzickJ, IngleJet al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol.28(3), 509–518 (2010).
   PubMed Web of Science ®Google Scholar
• Mocellin S , PilatiP, BriaravaM, NittiD. Breast cancer chemoprevention: a network meta-analysis of randomized controlled trials. J. Natl Cancer Inst.108(2), djv318 (2016).
   PubMedGoogle Scholar
• Goss PE , IngleJN, Ales-MartinezJEet al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med.364(25), 2381–2391 (2011).
   PubMed Web of Science ®Google Scholar
• Hartmann LC , SchaidDJ, WoodsJEet al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med.340(2), 77–84 (1999).
   PubMed Web of Science ®Google Scholar
• Kauff ND , SatagopanJM, RobsonMEet al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med.346(21), 1609–1615 (2002).
   PubMed Web of Science ®Google Scholar
• Rocco N , RispoliC, MojaLet al. Different types of implants for reconstructive breast surgery. Cochrane Database Syst. Rev. (5), CD010895 (2016).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT , AndersonGL, PrenticeRL, RossouwJE, AragakiAK, MansonJE. Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy’s influence on incidence and deaths from breast cancer. Climacteric18(3), 336–338 (2015).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR , LevinAM, EisenAet al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl Cancer Inst.91(17), 1475–1479 (1999).
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen BA , SeynaeveC, Van AsperenCJet al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J. Natl Cancer Inst.107(5), (2015).
   Google Scholar
• Chai X , DomchekS, KauffN, RebbeckT, ChenJ. RE: Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J. Natl Cancer Inst.107(9), (2015).
   PubMedGoogle Scholar
• Jatoi I . Bilateral mastectomy for unilateral breast cancer: a perplexing trend. Indian J. Surg. Oncol.6(4), 387–389 (2015).
   PubMedGoogle Scholar
• Van Den Broek AJ , Van’T VeerLJ, HooningMJet al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J. Clin. Oncol.34(5), 409–418 (2016).
   PubMed Web of Science ®Google Scholar
• Van Sprundel TC , SchmidtMK, RookusMAet al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer93(3), 287–292 (2005).
   PubMed Web of Science ®Google Scholar
• Riedl CC , LuftN, BernhartCet al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J. Clin. Oncol.33(10), 1128–1135 (2015).
   PubMed Web of Science ®Google Scholar
• Veronesi U , PaganelliG, VialeGet al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med.349(6), 546–553 (2003).
   PubMed Web of Science ®Google Scholar
• Freeman BS . Subcutaneous mastectomy for benign breast lesions with immediate or delayed prosthetic replacement. Plast. Reconstr. Surg. Transplant. Bull.30, 676–682 (1962).
   PubMedGoogle Scholar
• Mallon P , FeronJG, CouturaudBet al. The role of nipple-sparing mastectomy in breast cancer: a comprehensive review of the literature. Plast. Reconstr. Surg.131(5), 969–984 (2013).
   PubMed Web of Science ®Google Scholar
• Murthy V , ChamberlainRS. Nipple-sparing mastectomy in modern breast practice. Clin. Anat.26(1), 56–65 (2013).
   PubMed Web of Science ®Google Scholar
• Agha RA , WellsteadG, SagooHet al. Nipple sparing versus skin sparing mastectomy: a systematic review protocol. BMJ Open6(5), e010151 (2016).
   PubMed Web of Science ®Google Scholar
• Moreno L , LinossiC, EstebanIet al. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin. Transl. Oncol. doi: 10.1007/s12094-015-1470-0 (2016) ( Epub ahead of print).
   Google Scholar